<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": italic;} Open Forum Infect DisOpen Forum Infect DisofidOpen Forum" exact="Infectious" post="Diseases2328-8957Oxford University PressUS pmcid: 7313828 doi: 10.1093/ofid/ofaa232ofaa232 : Perspectives:"/>
 <result pre=": Perspectives: AcademicSubjects/MED00290: Editor's Choice An Early Test-and-Treat Strategy for" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 http://orcid.org/0000-0002-2598-1621SchifferJoshua T123JohnstonChristine13WaldAnna1345CoreyLawrence134[1], Vaccine and"/>
 <result pre="Perspectives: AcademicSubjects/MED00290: Editor's Choice An Early Test-and-Treat Strategy for Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 http://orcid.org/0000-0002-2598-1621SchifferJoshua T123JohnstonChristine13WaldAnna1345CoreyLawrence134[1], Vaccine and Infectious"/>
 <result pre="AcademicSubjects/MED00290: Editor's Choice An Early Test-and-Treat Strategy for Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 http://orcid.org/0000-0002-2598-1621SchifferJoshua T123JohnstonChristine13WaldAnna1345CoreyLawrence134[1], Vaccine and Infectious Diseases"/>
 <result pre="Editor's Choice An Early Test-and-Treat Strategy for Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 http://orcid.org/0000-0002-2598-1621SchifferJoshua T123JohnstonChristine13WaldAnna1345CoreyLawrence134[1], Vaccine and Infectious Diseases Division,"/>
 <result pre="Severe Acute Respiratory Syndrome Coronavirus 2 http://orcid.org/0000-0002-2598-1621SchifferJoshua T123JohnstonChristine13WaldAnna1345CoreyLawrence134[1], Vaccine and" exact="Infectious" post="Diseases Division, Fred Hutchinson Cancer Research CenterUSA[2], Clinical Research"/>
 <result pre="Acute Respiratory Syndrome Coronavirus 2 http://orcid.org/0000-0002-2598-1621SchifferJoshua T123JohnstonChristine13WaldAnna1345CoreyLawrence134[1], Vaccine and Infectious" exact="Diseases" post="Division, Fred Hutchinson Cancer Research CenterUSA[2], Clinical Research Division,"/>
 <result pre="2 http://orcid.org/0000-0002-2598-1621SchifferJoshua T123JohnstonChristine13WaldAnna1345CoreyLawrence134[1], Vaccine and Infectious Diseases Division, Fred Hutchinson" exact="Cancer" post="Research CenterUSA[2], Clinical Research Division, Fred Hutchinson Cancer Research"/>
 <result pre="Fred Hutchinson Cancer Research CenterUSA[2], Clinical Research Division, Fred Hutchinson" exact="Cancer" post="Research CenterUSA[3], Department of Medicine, University of WashingtonUSA[4], Department"/>
 <result pre="For commercial re-use, please contact journals.permissions@oup.comofaa232.pdf Abstract Abstract As coronavirus" exact="disease" post="2019 cases and deaths continue to expand globally, there"/>
 <result pre="evaluating therapies in patients who are already hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS CoV-2) infection. Given that"/>
 <result pre="therapies in patients who are already hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS CoV-2) infection. Given that the"/>
 <result pre="in patients who are already hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS CoV-2) infection. Given that the median"/>
 <result pre="to intervene early is being missed. Indeed, for many other" exact="viral" post="infections, early treatment soon after development of symptoms is"/>
 <result pre="soon after development of symptoms is associated with decreased mortality," exact="lower" post="hospitalization rates, and lower likelihood of transmission to others."/>
 <result pre="symptoms is associated with decreased mortality, lower hospitalization rates, and" exact="lower" post="likelihood of transmission to others. In this study, we"/>
 <result pre="Co-V-2 early during infection. Early treatment of SARS-CoV-2 could disproportionately" exact="lower" post="the mortality rate, but also lower hospitalization and decrease"/>
 <result pre="of SARS-CoV-2 could disproportionately lower the mortality rate, but also" exact="lower" post="hospitalization and decrease ongoing transmission of virus. antiviral therapy"/>
 <result pre="of virus. antiviral therapy COVID-19 SARS CoV-2 Funding Fred Hutchinson" exact="Cancer" post="Research Center10.13039/100005895 page-count: The global community is enduring the"/>
 <result pre="global community is enduring the horrific first wave of coronavirus" exact="disease" post="2019 (COVID-19). In many cities, emergency departments are inundated,"/>
 <result pre="of physical distancing will allow a rapid surge of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS CoV-2) infections [5]. Yet,"/>
 <result pre="physical distancing will allow a rapid surge of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS CoV-2) infections [5]. Yet, the"/>
 <result pre="distancing will allow a rapid surge of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS CoV-2) infections [5]. Yet, the economy"/>
 <result pre="surge of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2)" exact="infections" post="[5]. Yet, the economy and supply chain may not"/>
 <result pre="the economy and supply chain may not tolerate sustained or" exact="recurrent" post="shutdowns. Until there is widespread implementation of an effective"/>
 <result pre="To manage the pandemic, effective strategies are needed to treat" exact="infection" post="and lower its fatality rate. To this end, the"/>
 <result pre="the pandemic, effective strategies are needed to treat infection and" exact="lower" post="its fatality rate. To this end, the biology of"/>
 <result pre="CoV-2 provides a golden opportunity to diagnose and treat, before" exact="infection" post="becomes uncontrollable. The average time between development of symptoms"/>
 <result pre="between development of symptoms to death is 14â€&quot;21 days [7]." exact="Viral" post="kinetic studies demonstrate that early infection consists of a"/>
 <result pre="is 14â€&quot;21 days [7]. Viral kinetic studies demonstrate that early" exact="infection" post="consists of a 2- to 3-day surge in viral"/>
 <result pre="early infection consists of a 2- to 3-day surge in" exact="viral" post="loads, followed by a slow decline that persists for"/>
 <result pre="weeks [8â€&quot;10]. Initial symptoms develop around the period of maximum" exact="viral" post="load and represent an optimal time to intervene (Figure"/>
 <result pre="time to intervene (Figure 1). Figure 1. Schematic of severe" exact="acute" post="respiratory syndrome coronavirus 2 infection in a symptomatic person."/>
 <result pre="to intervene (Figure 1). Figure 1. Schematic of severe acute" exact="respiratory" post="syndrome coronavirus 2 infection in a symptomatic person. RNA,"/>
 <result pre="intervene (Figure 1). Figure 1. Schematic of severe acute respiratory" exact="syndrome" post="coronavirus 2 infection in a symptomatic person. RNA, ribonucleic"/>
 <result pre="Figure 1. Schematic of severe acute respiratory syndrome coronavirus 2" exact="infection" post="in a symptomatic person. RNA, ribonucleic acid. Symptoms often"/>
 <result pre="of severe acute respiratory syndrome coronavirus 2 infection in a" exact="symptomatic" post="person. RNA, ribonucleic acid. Symptoms often start in the"/>
 <result pre="symptomatic person. RNA, ribonucleic acid. Symptoms often start in the" exact="upper" post="respiratory tract and progress to dyspnea [8]. As was"/>
 <result pre="person. RNA, ribonucleic acid. Symptoms often start in the upper" exact="respiratory" post="tract and progress to dyspnea [8]. As was demonstrated"/>
 <result pre="was demonstrated for influenza in immunocompromised hosts [11], elimination of" exact="viral" post="replication during this early period may prevent progression to"/>
 <result pre="replication during this early period may prevent progression to significant" exact="lung disease." post="If widely implemented in vulnerable populations such as the"/>
 <result pre="the elderly, an early test-and-treat approach, applied at home, could" exact="lower" post="case fatality and hospitalization rates. Much like managing an"/>
 <result pre="10â€…000 cases rather than 10, managing a SARS CoV-2 lung" exact="infection" post="is more difficult when the entire tissue is overrun"/>
 <result pre="of Ebola treatment, shorter symptom duration at presentation correlated with" exact="lower" post="viral load, and it increased the likelihood that interventions"/>
 <result pre="Ebola treatment, shorter symptom duration at presentation correlated with lower" exact="viral" post="load, and it increased the likelihood that interventions would"/>
 <result pre="causes shorter duration of shedding and symptoms [13]. For human" exact="immunodeficiency" post="virus (HIV), early treatment confers mortality benefits and lowers"/>
 <result pre="15]. The benefits of early test-and-treat methods may not be" exact="limited" post="to the elderly. Life-threatening COVID-19 occurs in young, previously"/>
 <result pre="staff and transit workers who may be exposed to high" exact="viral" post="inoculums [16]. Even among those who recover, symptoms can"/>
 <result pre="of SARS CoV-2 transmission is attributed to asymptomatic and presymptomatic" exact="viral" post="shedding, many transmissions result from coughing and sneezing leading"/>
 <result pre="result from coughing and sneezing leading to airborne droplets. Household" exact="viral" post="load is a determinant of transmission for human herpesviruses"/>
 <result pre="Therapeutic reduction in shedding is linked with less transmission for" exact="herpes" post="simplex virus-2 [19]. Lowering viral load is a mainstay"/>
 <result pre="linked with less transmission for herpes simplex virus-2 [19]. Lowering" exact="viral" post="load is a mainstay of HIV prevention [20]. Even"/>
 <result pre="for influenza than SARS CoV-2, early oseltamivir initiation limits the" exact="secondary" post="attack rate to household contacts [21]. Despite multiple advantages"/>
 <result pre="on hospitalized patients. At this later stage of COVID-19, although" exact="viral" post="replication may augment disease progression, cytokine storm is an"/>
 <result pre="this later stage of COVID-19, although viral replication may augment" exact="disease" post="progression, cytokine storm is an increasingly relevant aspect of"/>
 <result pre="the use of biologics in the critically ill [22], and" exact="incomplete" post="efficacy of antiviral agents [23]. A rational therapeutic approach"/>
 <result pre="this available to citizens in cities with high burden of" exact="infection" post="[24]. Self-quarantine will be more likely if people know"/>
 <result pre="for a licensed agent, we propose smaller, rapid studies using" exact="viral" post="shedding metrics and symptoms as surrogate endpoints for risk"/>
 <result pre="Virologic endpoints are established surrogates of treatment efficacy for HIV," exact="hepatitis" post="B, hepatitis C, HSV-2, influenza, and cytomegalovirus [13, 25â€&quot;28]."/>
 <result pre="are established surrogates of treatment efficacy for HIV, hepatitis B," exact="hepatitis C," post="HSV-2, influenza, and cytomegalovirus [13, 25â€&quot;28]. It is likely"/>
 <result pre="that a profound reduction in shedding early during SARS Co-V-2" exact="infection" post="will translate into prevention of oxygen need and hospitalization."/>
 <result pre="special importance in high-risk populations such as senior centers and" exact="cancer" post="centers. Smaller and less expensive studies will allow a"/>
 <result pre="to infection, could be established for intravenous infusions. The ongoing" exact="Antibody" post="Mediated Prevention study for HIV, in which more than"/>
 <result pre="radiology, the goal should be to avoid severe infection. To" exact="lower" post="hospitalization rates during the inevitable second and third waves"/>
 <result pre="also suggest to diagnose early and treat early, which may" exact="lower" post="the hospitalization rate and lower the death rate. Acknowledgments"/>
 <result pre="and treat early, which may lower the hospitalization rate and" exact="lower" post="the death rate. Acknowledgments Financial support. J.T.S. receives COVID-19"/>
 <result pre="support. J.T.S. receives COVID-19 research funding from a Fred Hutchinson" exact="Cancer" post="Research Center internal grant. Potential conflicts of interest. All"/>
 <result pre="COVID-19 in Italy. JAMA2020; 323(18):1775â€&quot;6. 2.collab: Korean Society of Infectiouscollab:" exact="Diseases" post="and Korea Centers for Disease Control and Prevention. Analysis"/>
 <result pre="2.collab: Korean Society of Infectiouscollab: Diseases and Korea Centers for" exact="Disease" post="Control and Prevention. Analysis on 54 mortality cases of"/>
 <result pre="Control and Prevention. Analysis on 54 mortality cases of coronavirus" exact="disease" post="2019 in the Republic of Korea from January 19"/>
 <result pre="and Strategies for Mitigation and Suppression. WHO Collaborating Centre for" exact="Infectious" post="Disease Modelling, MRC Centre for Global Infectious Disease Analysis:"/>
 <result pre="Strategies for Mitigation and Suppression. WHO Collaborating Centre for Infectious" exact="Disease" post="Modelling, MRC Centre for Global Infectious Disease Analysis: Abdul"/>
 <result pre="Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global" exact="Infectious" post="Disease Analysis: Abdul Latif Jameel Institute for Disease and"/>
 <result pre="Centre for Infectious Disease Modelling, MRC Centre for Global Infectious" exact="Disease" post="Analysis: Abdul Latif Jameel Institute for Disease and Emergency"/>
 <result pre="for Global Infectious Disease Analysis: Abdul Latif Jameel Institute for" exact="Disease" post="and Emergency Analytics, Imperial College London, 2020. 5.KisslerSM, TedijantoC,"/>
 <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China. JAMA2020; 323(11):1061â€&quot;9. 7.YangX, YuY, XuJ, et"/>
 <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
 <result pre="PALM Consortium Study TeamA randomized, controlled trial of Ebola virus" exact="disease" post="therapeutics. N Engl J Med2019; 381:2293â€&quot;303.31774950 13.HaydenFG, SugayaN, HirotsuN,"/>
 <result pre="BabikerAG, GordinF, et al.Initiation of antiretroviral therapy in early asymptomatic" exact="HIV infection." post="N Engl J Med2015; 373:795â€&quot;807.26192873 15.DasM, ChuPL, SantosGM, et"/>
 <result pre="J Med2015; 373:795â€&quot;807.26192873 15.DasM, ChuPL, SantosGM, et al.Decreases in community" exact="viral" post="load are accompanied by reductions in new HIV infections"/>
 <result pre="community viral load are accompanied by reductions in new HIV" exact="infections" post="in San Francisco. PLoS One2010; 5:e11068.20548786 16.Severe outcomes among"/>
 <result pre="Francisco. PLoS One2010; 5:e11068.20548786 16.Severe outcomes among patients with coronavirus" exact="disease" post="2019 (COVID-19) â€&quot; United States, February 12â€&quot;March 16, 2020."/>
 <result pre="human herpesvirus 6 and cytomegalovirus transmission to Ugandan infants from" exact="viral" post="shedding in saliva by household contacts. Viruses2020; 12(2):171.. 19.CoreyL,"/>
 <result pre="Study GroupOnce-daily valacyclovir to reduce the risk of transmission of" exact="genital herpes." post="N Engl J Med2004; 350:11â€&quot;20.14702423 20.CohenMS, ChenYQ, McCauleyM, et"/>
 <result pre="al.Effects of oseltamivir treatment of index patients with influenza on" exact="secondary" post="household illness in an urban setting in Bangladesh: secondary"/>
 <result pre="on secondary household illness in an urban setting in Bangladesh:" exact="secondary" post="analysis of a randomised, placebo-controlled trial. Lancet Infect Dis2015;"/>
 <result pre="DuR, et al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="response end points for regulatory approval and dose selection of" exact="hepatitis C" post="therapies. Gastroenterology2013; 144:1450â€&quot;5.e2.23470616 26.MurrayJS, ElashoffMR, Iacono-ConnorsLC, et al.The use"/>
 <result pre="27.NatoriY, AlghamdiA, TazariM, et al.; collab: CMV Consensus ForumUse of" exact="viral" post="load as a surrogate marker in clinical studies of"/>
 <result pre="SelkeS, et al.Herpes simplex virus shedding rate: surrogate outcome for" exact="genital herpes" post="recurrence frequency and lesion rates, and phase 2 clinical"/>
 <result pre="et al.Herpes simplex virus shedding rate: surrogate outcome for genital" exact="herpes" post="recurrence frequency and lesion rates, and phase 2 clinical"/>
 <result pre="J Infect Dis2018; 218:1691â€&quot;9.30020484 29.MartinezMACompounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirus. Antimicrob Agents Chemother2020; 64(5):e00399-20. 30.GordonDE, JangGM, BouhaddouM,"/>
</results>
